Skip to main content

Table 4 Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer overall and subtypes of breast cancer, and the duration of estrogen and progestin therapy (EPT) by body mass index (BMI)

From: Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program

OVERALL breast cancer

 

BMI <25

BMI ≥25

Controls (n)

Cases (n)

OR*

95% CI

Controls (n)

Cases (n)

OR

95% CI

Duration of EPT (years)

 Never used

6154

1056

1

Reference

6880

1402

1

Reference

  < =5

1740

316

1.20

(1.00, 1.44)

1812

420

1.13

(0.97, 1.32)

 >5

1623

495

1.96

(1.64, 2.34)

1615

456

1.31

(1.12, 1.54)

  p-trend*

  

<0.0001

   

<0.0001

 

  p for interaction

  

0.001

     

Luminal A-like breast cancer

 Duration of EPT (years)

  Never used

3424

550

1

Reference

3892

789

1

Reference

   < =5

959

176

1.36

(1.06, 1.74)

987

243

1.22

(0.99, 1.50)

  >5

896

293

2.29

(1.80, 2.91)

906

270

1.38

(1.12, 1.71)

   p-trend

  

<0.0001

   

0.002

 

   p for interaction

  

0.001

     

Luminal B-like HER2-negative breast cancer

 Duration of EPT (years)

  Never used

850

173

1

Reference

887

178

1

Reference

   < =5

257

57

1.13

(0.74, 1.71)

295

59

0.83

(0.54, 1.29)

  >5

243

71

1.22

(0.79, 1.88)

256

47

0.83

(0.51, 1.35)

   p-trend

  

0.34

   

0.37

 

   p for interaction

  

0.03

     

Luminal B-like HER2-positive breast cancer

 Duration of EPT (years)

  Never used

450

81

1

Reference

544

113

1

Reference

   < =5

137

16

0.85

(0.40, 1.81)

144

29

0.82

(0.45, 1.49)

  >5

127

28

1.56

(0.67, 3.60)

130

43

1.56

(0.87, 2.78)

   p-trend

  

0.44

   

0.24

 

   p for interaction

  

0.52

     

HER2-positive breast cancer

 Duration of EPT (years)

  Never used

269

54

1

Reference

296

56

1

Reference

   < =5

80

16

1.14

(0.44, 2.95)

77

14

1.38

(0.62, 3.08)

  >5

49

13

1.53

(0.57, 4.05)

57

17

1.28

(0.56, 2.93)

   p-trend

  

0.41

   

0.43

 

   p for interaction

  

0.89

     

Triple-negative breast cancer

 Duration of EPT (years)

  Never used

457

94

1

Reference

522

101

1

Reference

   < =5

123

20

0.96

(0.45, 2.04)

110

34

1.40

(0.79, 2.47)

  >5

113

25

1.27

(0.56, 2.86)

100

27

1.34

(0.71, 2.54)

   p-trend

  

0.63

   

0.25

 

   p for interaction

  

0.09

     
  1. *p for trend and ORs mutually adjusted for age (50–54, 55–59, 60–64, 65–70 years at screening), BMI (≤22, 23–25, 26–28, >28 at screening), age at menarche (9–12, 13, 14, 15–18), education (no education/primary school, high school, bachelor’s or master’s degree), number of pregnancies (0, 1, 2, 3, ≥4), menopausal status (premenopausal, perimenopausal, postmenopausal). HER2 human epidermal growth factor receptor 2